Total Payments
$241,869
2024 Payments
$14,179
Companies
28
Transactions
490
Medicare Patients
12,545
Medicare Billing
$8.4M
Payment Breakdown by Category
Other$205,974 (85.2%)
Food & Beverage$12,910 (5.3%)
Consulting$11,750 (4.9%)
Travel$10,824 (4.5%)
Education$411.92 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $205,374 | 103 | 84.9% |
| Food and Beverage | $12,910 | 295 | 5.3% |
| Consulting Fee | $11,750 | 5 | 4.9% |
| Travel and Lodging | $10,824 | 71 | 4.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $600.00 | 1 | 0.2% |
| Education | $411.92 | 15 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $128,375 | 228 | $0 (2024) |
| Genentech USA, Inc. | $39,283 | 54 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $31,208 | 67 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $30,734 | 51 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,605 | 9 | $0 (2019) |
| AbbVie, Inc. | $1,985 | 4 | $0 (2017) |
| Pinnacle Biologics, Inc | $1,677 | 7 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,460 | 7 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $826.99 | 9 | $0 (2022) |
| Inspire Medical Systems, Inc. | $404.88 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,179 | 36 | AstraZeneca Pharmaceuticals LP ($7,970) |
| 2023 | $12,738 | 46 | GlaxoSmithKline, LLC. ($9,690) |
| 2022 | $18,061 | 45 | GlaxoSmithKline, LLC. ($13,336) |
| 2021 | $28,487 | 49 | GlaxoSmithKline, LLC. ($19,273) |
| 2020 | $11,756 | 25 | GlaxoSmithKline, LLC. ($8,342) |
| 2019 | $95,347 | 128 | GlaxoSmithKline, LLC. ($67,664) |
| 2018 | $37,170 | 100 | Sunovion Pharmaceuticals Inc. ($16,633) |
| 2017 | $24,130 | 61 | Genentech USA, Inc. ($11,115) |
All Payment Transactions
490 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $121.13 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $117.20 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $5.72 | General |
| Category: RESPIRATORY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $60.31 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $45.68 | General |
| Category: NEUROLOGY | ||||||
| 09/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $123.48 | General |
| Category: NEUROLOGY | ||||||
| 08/19/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Education | In-kind items and services | $94.95 | General |
| Category: Immunology | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: RESPIRATORY | ||||||
| 08/07/2024 | Fisher & Paykel Healthcare Inc | FISHER & PAYKEL HEALTHCARE (Device), FISHER & PAYKEL HEALTHCARE, FISHER & PAYKEL HEALTHCARE | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: Sleep | ||||||
| 07/26/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $78.99 | General |
| Category: Cardiology | ||||||
| 07/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: IMMUNOLOGY | ||||||
| 07/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 06/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: IMMUNOLOGY | ||||||
| 05/29/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $7.53 | General |
| Category: Inflammation | ||||||
| 05/15/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $33.92 | General |
| Category: Immunology | ||||||
| 05/15/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 3,205 | 106,739 | $5.3M | $3.0M |
| 2022 | 30 | 3,209 | 62,869 | $4.1M | $2.2M |
| 2021 | 31 | 3,082 | 48,042 | $3.2M | $1.7M |
| 2020 | 36 | 3,049 | 35,832 | $2.6M | $1.4M |
Total Patients
12,545
Total Services
253,482
Medicare Billing
$8.4M
Procedure Codes
137
All Medicare Procedures & Services
137 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2182 | Injection, mepolizumab, 1 mg | Office | 2023 | 40 | 43,200 | $1.7M | $1.0M | 58.0% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 29 | 4,920 | $851,160 | $651,493 | 76.5% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 30 | 20,559 | $1.3M | $619,639 | 48.0% |
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 20 | 31,710 | $634,200 | $455,278 | 71.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 341 | 1,412 | $212,204 | $82,065 | 38.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 119 | 1,192 | $158,903 | $61,656 | 38.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 526 | 856 | $90,632 | $32,141 | 35.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 255 | 281 | $69,415 | $26,253 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 196 | 276 | $46,862 | $17,159 | 36.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 93 | 93 | $38,433 | $13,290 | 34.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 86 | 346 | $32,261 | $12,274 | 38.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 68 | $15,286 | $6,038 | 39.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 162 | 162 | $14,742 | $5,764 | 39.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 44 | $14,594 | $5,318 | 36.4% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 138 | 139 | $14,565 | $5,187 | 35.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 66 | 66 | $8,580 | $5,003 | 58.3% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 100 | 100 | $11,800 | $4,600 | 39.0% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 15 | 16 | $8,480 | $4,507 | 53.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 26 | $13,442 | $4,121 | 30.7% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 68 | 110 | $9,790 | $3,810 | 38.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 92 | 379 | $10,146 | $3,804 | 37.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 91 | 93 | $9,393 | $3,563 | 37.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 16 | 17 | $8,842 | $3,304 | 37.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 109 | 109 | $5,438 | $3,121 | 57.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 69 | 104 | $7,800 | $3,027 | 38.8% |
About Dr. Raja Devanathan, M.D
Dr. Raja Devanathan, M.D is a Pulmonary Disease healthcare provider based in Hobart, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871587220.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raja Devanathan, M.D has received a total of $241,869 in payments from pharmaceutical and medical device companies, with $14,179 received in 2024. These payments were reported across 490 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($205,374).
As a Medicare-enrolled provider, Devanathan has provided services to 12,545 Medicare beneficiaries, totaling 253,482 services with total Medicare billing of $8.4M. Data is available for 4 years (2020–2023), covering 137 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Hobart, IN
- Active Since 08/31/2005
- Last Updated 02/12/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1871587220
Products in Payments
- NUCALA (Biological) $82,577
- Xolair (Biological) $38,746
- TRELEGY ELLIPTA (Drug) $35,260
- LONHALA MAGNAIR (Drug) $16,307
- FASENRA (Drug) $12,825
- UTIBRON (Drug) $11,104
- FASENRA (Biological) $9,165
- TEZSPIRE (Biological) $8,637
- ANORO (Drug) $4,682
- SEEBRI (Drug) $3,796
- XOLAIR (Biological) $3,093
- Photofrin (Drug) $1,677
- OFEV (Drug) $1,164
- XARELTO (Drug) $826.99
- ANORO ELLIPTA (Drug) $629.73
- INSPIRE (Device) $404.88
- GILENYA (Drug) $396.00
- Monarch Platform (Device) $315.75
- PRALUENT (Drug) $219.45
- SIR-Spheres Microspheres (Device) $211.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.